Based on the results of the FLAURA trial, which demonstrated the efficacy of osimertinib as a first-line treatment for patients with EGFR mutation-positive NSCLC, this agent can be administered as a first-line therapy to eligible patients without requiring T790M mutation analysis beforehand [31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.